Trial of Psilocybin versus Escitalopram for Depression
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(10):14 N Engl J Med. 2021 14-Feb;():. 10.1056/NEJMoa2032994What this means for my practice?
From baseline, the change in depression scores on the QIDS-SR-16 at week six was not significantly different between the two trial groups. The secondary outcome measures favoured psilocybin over escitalopram, but there was no correction for multiple comparisons for the analyses of these outcomes. The results are limited by the short escitalopram treatment duration, and the recruited patients' preference for psilocybin over escitalopram. Additionally, the effectiveness of the blinding was not assessed, and the sample was homogeneous in terms of ethnic and socioeconomic backgrounds.
Study Summary
Fifty-nine patients with prolonged, moderate-to-severe major depressive disorder underwent a double-blind, randomized controlled trial to compare the effects of psilocybin with escitalopram. Patients were assigned to the psilocybin group or escitalopram group. For 6 weeks, the psilocybin group patients received two doses of psilocybin (25 mg), along with a placebo. The escitalopram group received two doses of psilocybin (1 mg), along with escitalopram. The primary outcome measure was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology- Self-Report (QIDS-SR-16). There were no significant differences on these scores between the two groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
